Drug intelligence / Profile preview

tobevibart + tenofovir disoproxil fumarate

Development stage: Unknown
Lead developer: Vir Biotechnology
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Subcutaneous (tobevibart), Oral (tenofovir Disoproxil Fumarate)

Overview

This is a **combination drug** composed of tobevibart (VIR-3434) and tenofovir disoproxil fumarate. **Tobevibart** is a monoclonal antibody engineered to target the antigenic loop of the hepatitis B surface antigen (HBsAg). Its mechanism includes inhibition of viral entry (neutralization) for hepatitis B and hepatitis delta viruses and clearance of free virions through opsonization[2][4][6]. **Tenofovir disoproxil fumarate** is a nucleotide analog reverse transcriptase inhibitor (NtRTI) that acts by inhibiting reverse transcriptase, an enzyme essential for genetic material replication in viruses such as HIV and hepatitis B, leading to chain termination and suppression of viral replication[1]. This combination likely aims to provide dual antiviral activity targeting viral entry and replication in HBV/HDV infection. Tobevibart is developed by Vir Biotechnology and is investigational for HBV/HDV; tenofovir disoproxil fumarate is a widely approved antiviral.

Other names: tobevibart + tenofovir disoproxil fumarate

Targets

HBsAg (Hepatitis B surface antigen)HBV Pol (Hepatitis B virus polymerase)

Beyond the preview

Go deeper on tobevibart + tenofovir disoproxil fumarate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tobevibart + tenofovir disoproxil fumarate.

Explore the full profile